Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Do you avoid adding high energy photons (with associated neutrons) for younger breast cancer patients, out of concern for secondary malignancy risk?
Answer from: Radiation Oncologist at Community Practice
We used mixed, whenever appropriate, with optimization of dose distribution using field within field technique (no wedges).
Sign In
or
Register
to read more
9244
Related Questions
In what patients is it inappropriate to offer DCISionRT testing?
How do your PMRT recommendations change with ITCs after neoadjuvant chemotherapy if they had SLNB only versus ALND in light of B51?
How does a pathological CR to neoadjuvant chemotherapy influence your practice for the use of bolus with adjuvant PMRT patients without inflammatory breast cancer, but who would meet traditional risk factors for skin involvement?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
How would you manage an elderly patient with a de novo TNBC in the setting of a remote prior ipsilateral breast cancer s/p mastectomy and implant?
How do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies for patients with germline BRCA1/2 mutations?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?
What are your top takeaways in Medical Oncology from SABCS 2024?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?